Global Glycobiology Market Size, Share, Trends, COVID-19 impact, Growth Analysis Report – Segmented By Product, Application, End-User & Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) – Industry Forecasts (2024 to 2029)

Updated On: June, 2024
ID: 6742
Pages: 175

Glycobiology Market Size and Growth (2023 to 2028)

The global glycomics market size is projected to be worth USD 1962.52 Million by 2028 from USD 1055.8 Million in 2023, growing at a compound annual growth rate of 13.2% between 2023 to 2028. 

Glycobiology is the study of fundamental biology, includes the structure and function of the molecules containing carbohydrates. It plays a vital role in biotechnological research and biomedicine. Carbohydrates control all the cellular process aspects that involve cell to cell interactions, blood clotting, regulating hormonal activity, and signaling for growth factor also directs embryonic development. The pharmaceutical and biotech companies are investing in the research and development activities of superior biological products. Products such as glycobiology and other products come under proteomics. Glycomics biomarkers have significant applications in drug development and diagnostics for many diseases. According to the reports, the Australian government invested USD 10.4 billion for scientific and research and development activities between 2017 and 2018. 


High investments for the R&D by the pharmaceutical giants for the glycomics segment and technological advancements are primarily attributing the growth for the global glycobiology market.

The growth of the global glycobiology market is majorly driven by rising R&D investments in pharmaceutical and biotechnology companies, growth in the proteomics market, and increasing research activities on glycomics. In recent times, companies such as Thermo Fisher Scientific and Agilent Technologies have invested USD 888 Mn and USD 339 Mn, respectively, in the R&D activities in their companies in the glycobiology segment. This particular attribute is expected to add fuel to the growth rate of the market during the forecast period.

On the other hand, the growing demand for glycomics research techniques for conducting a comprehensive study on glycomics is propelling the market's growth rate to the extent. Rising investments in the development of the healthcare infrastructure by government organizations are likely to fuel the market demand.


However, the high cost associated with the imaging tools and the strict government policies is expected to impede the global glycomics market growth during the forecast period. 

Impact of COVID-19 on the global glycobiology market:

Coronavirus is an infectious disease. World health organization announced the covid-19 as a pandemic and emergence of healthcare. To control the spread of COVID-19, the governments had imposed nationwide lockdown and a ban on flights. The COVID-19 had negatively impacted the Glycobiology market during the first half of 2020; the market had a downfall because all the concerned activities on glycomics had been stopped and postponed. However, the second half of 2020 has shown a positive impact on glycomics as all the activities were resumed by taking preventive measures issued by government organizations.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By Product, Application, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Thermo Fisher Scientific, Inc. Merck KGaA, Agilent Technologies, Bruker, New England Biolabs, Danaher, Shimadzu Corporation, and Takara Bio, Inc.


This research report on the global glycobiology market has been segmented & sub-segmented based on the product, application, instruments, end-user, and region.

Glycobiology Market - By Product:

  • Enzymes  
    • Glycosidases
    • Neuraminidases
    • Glycosyltransferases
    • Sialyltransferases
    • Others
  • Instruments
    • HPLS         
    • Mass Spectrometry            
    • MALDITOF              
  • Kits
    • Glycan Labeling Kits
    • Glycan Purification Kits
    • Glycan Release Kits
    • Others
  • Reagents
    • Glycoproteins
    • Monosaccharides
    • Oligosaccharides
    • Others

Based on the product type, the instruments segment was accounted for most of the market share among all in 2022, whereas the enzymes segment also had decent occupancy and recorded 35%. Among various sub-segments of enzymes, the Glycosidases sub-segment is forecasted to grow at an aggressive rate during the forecast period.

Based on the instrument, the HPLS columns was the leader in 2022, and it is expected to account for a larger share and dominate the market during the forecast period. 

Glycobiology Market - By Application:

  • Diagnostic
  • Drug Discovery      
  • Oncology 

Based on the application, the drug discovery segment is the leading application segment with influential factors such as a rising number of research and development activities in pharmaceutical and biotechnical companies, and an increasing number of drug discovery R&D activities in academic research institutions are boosting the market growth during the forecast period. 

Glycobiology Market - By End User:

  • Academic Research Institutes          
  • Pharmaceutical & Biotechnology Companies            
  • Contract Research Organizations 

Based on the end-user, academic research institutes are the leading segment with the majority market share. It is expected to grow at a significant rate during the forecast period. Increasing research and development activities in academic research institutes and government investment for scientific & research activities propel market growth. 

Glycobiology Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North American market held the majority market share of the global glycobiology market in 2021 and predicted the dominance would be continuing throughout the forecast period. The presence of pharmaceutical and biopharmaceutical companies and increased research and development activities in research institutes are expected to create the demand for the glycobiology market in this region.

The European market was the second leading region in the global glycobiology market in 2021 due to the number of research activities. The growing demand for glycomics research techniques is creating the demand for the glycobiology market.

The Asia Pacific glycobiology market is anticipated to register the highest CAGR during the market forecast period owing to the increasing geriatric population and rising demand to promote quality treatment services. 

Middle East Africa held the largest share, and it is expected to record an increasing CAGR during the market forecast period. Factors such as the presence of key pharmaceutical and biopharmaceutical companies, growth in the proteomic market, and increasing research activities on glycomics are anticipated to increase the market growth over the forecast period.


Companies playing a promising role in the global glycobiology market analyzed in this report are Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Bruker, New England Biolabs, Danaher, Shimadzu Corporation, and Takara Bio, Inc.


  • In June 2019, the InfinityLab LC/MSD iQ System was launched by Agilent Technologies (US). 
  • In June 2018, the UHMR Hybrid Quadrupole-Orbitrap Mass Spectrometer had been launched by Thermo fisher scientific.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample